[go: up one dir, main page]

WO2009062746A3 - Topische arzneimittel zur antimykotischen therapie - Google Patents

Topische arzneimittel zur antimykotischen therapie Download PDF

Info

Publication number
WO2009062746A3
WO2009062746A3 PCT/EP2008/009686 EP2008009686W WO2009062746A3 WO 2009062746 A3 WO2009062746 A3 WO 2009062746A3 EP 2008009686 W EP2008009686 W EP 2008009686W WO 2009062746 A3 WO2009062746 A3 WO 2009062746A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical drugs
antifungal therapy
antifungal
drugs
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/009686
Other languages
English (en)
French (fr)
Other versions
WO2009062746A2 (de
Inventor
Marianne Petersen-Braun
Sabine Glaeser
Norbert Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Priority to AU2008323165A priority Critical patent/AU2008323165A1/en
Priority to MX2010005385A priority patent/MX2010005385A/es
Priority to EP08850735A priority patent/EP2222319A2/de
Priority to CA2705815A priority patent/CA2705815A1/en
Publication of WO2009062746A2 publication Critical patent/WO2009062746A2/de
Publication of WO2009062746A3 publication Critical patent/WO2009062746A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft topische Arzneimittel zur antimykotischen Therapie, welche mindestens einen antimykotischen Wirkstoff sowie mindestens einen aus der Pantothensäure und Pantothensäurederivate umfassenden Gruppe ausgewählten Wirkstoff in fixer Kombination enthalten.
PCT/EP2008/009686 2007-11-17 2008-11-15 Topische arzneimittel zur antimykotischen therapie Ceased WO2009062746A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008323165A AU2008323165A1 (en) 2007-11-17 2008-11-15 Topical drugs for use in antifungal therapy
MX2010005385A MX2010005385A (es) 2007-11-17 2008-11-15 Medicamentos topicos para la terapia antimicotica.
EP08850735A EP2222319A2 (de) 2007-11-17 2008-11-15 Topische arzneimittel zur antimykotischen therapie
CA2705815A CA2705815A1 (en) 2007-11-17 2008-11-15 Topical drugs for use in antifungal therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07022353.2 2007-11-17
EP07022353 2007-11-17

Publications (2)

Publication Number Publication Date
WO2009062746A2 WO2009062746A2 (de) 2009-05-22
WO2009062746A3 true WO2009062746A3 (de) 2009-08-13

Family

ID=40214317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/009686 Ceased WO2009062746A2 (de) 2007-11-17 2008-11-15 Topische arzneimittel zur antimykotischen therapie

Country Status (5)

Country Link
EP (1) EP2222319A2 (de)
AU (1) AU2008323165A1 (de)
CA (1) CA2705815A1 (de)
MX (1) MX2010005385A (de)
WO (1) WO2009062746A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166840B1 (de) 2007-06-20 2017-01-11 The Trustees of Columbia University in the City of New York Biofilmresistente oberflächen
US9511040B2 (en) 2007-06-20 2016-12-06 The Trustees Of Columbia University In The City Of New York Skin and surface disinfectant compositions containing botanicals
US9687429B2 (en) 2007-06-20 2017-06-27 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing low concentrations of botanicals
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
JP2012532141A (ja) * 2009-06-30 2012-12-13 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 植物性成分を含有する抗微生物／防腐組成物
IT1400726B1 (it) * 2009-07-24 2013-07-02 Vi Rus S R L Composizione di un'emulsione ad uso topico a base di clotrimazolo, clorexidina digluconato,acido salicilico,allantoina,pantenolo,zinco,acido glicirretico,olio di mandorle dolci,olio di riso,mentile lattato indicata nel trattamento delle infezioni micotiche della cute e dei suoi annessi.
WO2011061155A1 (en) * 2009-11-17 2011-05-26 Bayer Consumer Care Ag Antifungal formulations and their use
GB201107176D0 (en) * 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
EP2773334B1 (de) 2011-11-03 2019-08-28 The Trustees of Columbia University in the City of New York Zusammensetzung mit verzögerter antimikrobieller wirkung
US9968101B2 (en) 2011-11-03 2018-05-15 The Trustees Of Columbia University In The City Of New York Botanical antimicrobial compositions
TW201330856A (zh) 2011-12-06 2013-08-01 Univ Columbia 廣效性的天然防腐組成物
EP2906197A1 (de) 2012-10-09 2015-08-19 The Procter & Gamble Company Verfahren zur identifizierung synergistischer kosmetischer kombinationen
EP2906946A1 (de) 2012-10-09 2015-08-19 The Procter & Gamble Company Verfahren zur identifikation oder bewertung nützlicher wirkstoffe und zusammensetzungen damit
WO2017031075A1 (en) * 2015-08-17 2017-02-23 Arno Therapeutics, Inc. Methods and compositions for enhanced transungual delivery of ar-12
WO2017091167A1 (en) * 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Topical pharmaceutical composition comprising fusidic acid, isoconazole, dexpanthenol and hydrocortisone
KR102217617B1 (ko) * 2020-08-14 2021-02-19 비엘엔에이치 주식회사 백선의 예방 또는 치료용 약학적 조성물
CN113440483B (zh) * 2021-06-30 2023-04-07 佛山市南海东方澳龙制药有限公司 一种犬用盐酸特比萘芬喷剂及其制备方法
WO2024137780A1 (en) * 2022-12-21 2024-06-27 Yale University Pank modulators and methods of treatment using same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2338248A1 (fr) * 1976-01-14 1977-08-12 Daunit Jeannine Pantothenate de zinc et procede d'obtention
RO107824B1 (ro) * 1991-01-30 1994-01-31 Maria Gaidargiu Șampon pentru păr
WO1999049835A1 (en) * 1998-03-31 1999-10-07 Johnson And Johnson Consumer Companies, Inc. An acidified composition for topical treatment of nail and skin conditions
WO2000015202A2 (de) * 1998-09-10 2000-03-23 Ipr-Institute For Pharmaceutical Research Ag Topisch anwendbare mittel
WO2005063224A1 (de) * 2003-12-23 2005-07-14 Merckle Gmbh Topische zubereitungen enthaltend dimethylsulfoxid und dexpanthenol
EP1557375A1 (de) * 2004-01-23 2005-07-27 Neubourg Skin Care GmbH & Co. KG Nageltinktur-Sprühdose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059297A2 (en) * 2002-01-21 2003-07-24 Slovakofarma A.S. Dermatological topical compositions and a process for the preparation thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2338248A1 (fr) * 1976-01-14 1977-08-12 Daunit Jeannine Pantothenate de zinc et procede d'obtention
RO107824B1 (ro) * 1991-01-30 1994-01-31 Maria Gaidargiu Șampon pentru păr
WO1999049835A1 (en) * 1998-03-31 1999-10-07 Johnson And Johnson Consumer Companies, Inc. An acidified composition for topical treatment of nail and skin conditions
WO2000015202A2 (de) * 1998-09-10 2000-03-23 Ipr-Institute For Pharmaceutical Research Ag Topisch anwendbare mittel
WO2005063224A1 (de) * 2003-12-23 2005-07-14 Merckle Gmbh Topische zubereitungen enthaltend dimethylsulfoxid und dexpanthenol
EP1557375A1 (de) * 2004-01-23 2005-07-27 Neubourg Skin Care GmbH & Co. KG Nageltinktur-Sprühdose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199505, Derwent World Patents Index; AN 1995-034091, XP002511041 *
See also references of EP2222319A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin

Also Published As

Publication number Publication date
CA2705815A1 (en) 2009-05-22
EP2222319A2 (de) 2010-09-01
WO2009062746A2 (de) 2009-05-22
AU2008323165A1 (en) 2009-05-22
MX2010005385A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
WO2009062746A3 (de) Topische arzneimittel zur antimykotischen therapie
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2123274A4 (de) Medizinische zusammensetzung zur transdermalen absorption, aufbewahrungseinheit für eine medizinische zusammensetzung und diese verwendende transdermale absorptionszubereitung
WO2010030598A3 (en) Pharmaceutical formulations comprising pemetrexed
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
IL206395A (en) N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
ZA200903160B (en) Sulfonyl-Phenyl-2H-[1,2,4]Oxodiazol-5-one Derivatives, Processes for their preparation and their use as pharmaceuticals
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2007133944A3 (en) Topical administration of acyclovir
EP2166015A4 (de) Lincosamidderivat und dieses als wirkstoff enthaltendes antibakterielles mittel
ZA201009097B (en) C-ring-substituted pregn-4-ene-21,17-carbolactone,and pharmaceutical preparations comprising the latter
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
WO2011058336A3 (en) Tablet comprising gum arabic
ZA200802187B (en) Drug delivery system for topical administration
WO2006128847A3 (en) Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
WO2009010298A3 (en) Paullone derivatives and its use
IL206383A0 (en) 15,16-methylene-17-(1'-propenyl)-17-3-oxidoestra-4-en-3'-one derivative, use thereof, and medicament containing said derivative
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
WO2007093168A3 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung
WO2009054483A1 (ja) サリューシン-βを含む医薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08850735

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008850735

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2705815

Country of ref document: CA

Ref document number: MX/A/2010/005385

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008323165

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008323165

Country of ref document: AU

Date of ref document: 20081115

Kind code of ref document: A